DNA2.0 Expands To New Menlo Park Facility
DNA2.0, the leading gene synthesis and protein engineering company, announced today that it has moved to a new, state-of-the-art facility in the heart of Silicon Valley and the Menlo Park technology corridor. DNA2.0 chose the 23,000 square foot space to accommodate the company's rapid growth—especially in the development of gene design and optimization technologies.
Menlo Park has been DNA2.0's home since the company's inception, and we have benefitted greatly from our proximity to the respected research institutions of the Bay Area, as well the region's leadership in technological innovation,” said Jeremy Minshull, PhD., CEO of DNA2.0. Our new facility provides an excellent venue for ramping up our research and development efforts while continuing to provide the quick, dependable service and support that our customers around the globe rely on.”
To reflect the company's growth, DNA2.0 has also restructured its management team, naming Dr. Jeremy Minshull as CEO. Dr. Claes Gustafsson has been named Chief Operating Officer and will continue to be responsible for the company's external communications, sales and marketing. Dr. Jon Ness will lead DNA2.0's technology development as Chief Scientific Officer while Dr. Sridhar Govindarajan has been named Chief Information Officer for his leadership role in the company's automation and engineering efforts.
IP Protection and Superior Customer Service
While many other gene synthesis companies offshore manufacturing to areas of the world with lax IP protection, all DNA2.0 genes are made at the company's state-of-the-art facility in Menlo Park, thus ensuring the greatest security for patented or confidential sequences. DNA2.0 guarantees researchers high-quality synthetic genes, delivered on time, every time.
About DNA2.0, Inc.
Founded in 2003, DNA2.0 is the leading gene synthesis and protein engineering company. It is the fastest provider of synthetic genes, based in the US with a global customer base encompassing academia, government and the pharmaceutical, chemical, agricultural and biotechnology industries. DNA2.0 has provided genes to thousands of customers, for whom it has synthesized many millions of base pairs. DNA2.0 explores novel applications for synthetic genes and is exploiting the synergy between highly efficient gene synthesis process and new protein optimization technologies. The tools and applications brought to market by DNA2.0 are transforming biology into an engineering discipline. The company is privately held and is headquartered in Menlo Park, Calif. For more information, please visit www.DNA20.com or email Claes Gustafsson, COO: cgustafsson@DNA20.com.